Literature DB >> 15474113

Drug delivery to the inner ear using gene therapy.

Hinrich Staecker1, Douglas E Brough, Mark Praetorius, Kim Baker.   

Abstract

The last 10 years have seen the development of numerous strategies for the delivery of genes to the inner ear. Besides being a useful research tool,gene therapy has significant promise as a potential clinical treatment. The human inner ear is easily accessible through either the round window or the stapes footplate. It is now possible to choose a variety of vectors to target a variety of different tissues. Modification of promoters yields different expression patterns as well as differences in degree of expression. Several animal studies have also demonstrated that expression of exogenous genes in the cochlea does not result in loss of hearing function. A variety of potential clinical applications are already evident from these early studies. Protective strategies such as prevention of neuronal degeneration and protection of auditory hair cells from oxidative stress are potential examples where gene therapy may be useful. As the understanding of gene therapy improves, investigators will be able to move toward targeted single-gene replacement to treat disorders such as connexin mutations and applying gene therapy to sensory cell replacement.

Entities:  

Mesh:

Year:  2004        PMID: 15474113     DOI: 10.1016/j.otc.2004.05.001

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  16 in total

Review 1.  The molecular basis of neurosensory cell formation in ear development: a blueprint for hair cell and sensory neuron regeneration?

Authors:  Bernd Fritzsch; Kirk W Beisel; Laura A Hansen
Journal:  Bioessays       Date:  2006-12       Impact factor: 4.345

Review 2.  [Hearing with combined electric acoustic stimulation].

Authors:  U Baumann; S Helbig
Journal:  HNO       Date:  2009-06       Impact factor: 1.284

Review 3.  [Intracochlear drug delivery in combination with cochlear implants : Current aspects].

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2016-11       Impact factor: 1.284

Review 4.  Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research.

Authors:  Hinrich Staecker; Mark Praetorius; Douglas E Brough
Journal:  Hear Res       Date:  2011-01-18       Impact factor: 3.208

5.  Optimizing atoh1-induced vestibular hair cell regeneration.

Authors:  Hinrich Staecker; Christina Schlecker; Shannon Kraft; Mark Praetorius; Chi Hsu; Douglas E Brough
Journal:  Laryngoscope       Date:  2014-06-17       Impact factor: 3.325

6.  Atoh1 induces auditory hair cell recovery in mice after ototoxic injury.

Authors:  Shannon Kraft; Chi Hsu; Douglas E Brough; Hinrich Staecker
Journal:  Laryngoscope       Date:  2013-03-11       Impact factor: 3.325

7.  Localized cell and drug delivery for auditory prostheses.

Authors:  Jeffrey L Hendricks; Jennifer A Chikar; Mark A Crumling; Yehoash Raphael; David C Martin
Journal:  Hear Res       Date:  2008-06-07       Impact factor: 3.208

Review 8.  Connexin 43 a check-point component of cell proliferation implicated in a wide range of human testis diseases.

Authors:  Daniel Chevallier; Diane Carette; Dominique Segretain; Jérome Gilleron; Georges Pointis
Journal:  Cell Mol Life Sci       Date:  2012-08-24       Impact factor: 9.261

Review 9.  Inner ear drug delivery for auditory applications.

Authors:  Erin E Leary Swan; Mark J Mescher; William F Sewell; Sarah L Tao; Jeffrey T Borenstein
Journal:  Adv Drug Deliv Rev       Date:  2008-09-21       Impact factor: 15.470

10.  Gene transfer in human vestibular epithelia and the prospects for inner ear gene therapy.

Authors:  Bradley W Kesser; George T Hashisaki; Jeffrey R Holt
Journal:  Laryngoscope       Date:  2008-05       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.